| Item Type | Name |
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Receptors, Tumor Necrosis Factor
|
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Crohn's disease: step up or top down therapy.
|
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
|
Academic Article
|
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
|
|
Academic Article
|
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
|
|
Academic Article
|
Refining the role of TNF antagonists for Crohn's disease. Introduction.
|
|
Academic Article
|
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
|
|
Academic Article
|
Selecting appropriate anti-TNF agents in inflammatory bowel disease.
|
|
Academic Article
|
Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty.
|
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
|
Academic Article
|
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity.
|
|
Academic Article
|
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
|
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
|
Academic Article
|
The role of biologics in ulcerative colitis.
|
|
Academic Article
|
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
|
|
Academic Article
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
The 'tipping point' applied.
|
|
Academic Article
|
Practical application of anti-TNF therapy for luminal Crohn's disease.
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
|
|
Academic Article
|
Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.
|
|
Academic Article
|
Commentary: pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis.
|
|
Academic Article
|
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
|
|
Academic Article
|
Still in pursuit.
|
|
Academic Article
|
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
|
|
Academic Article
|
Comparing guidelines for the treatment of inflammatory bowel disease.
|
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
|
Academic Article
|
Briakinumab for treatment of Crohn's disease: results of a randomized trial.
|
|
Academic Article
|
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
|
|
Academic Article
|
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis.
|
|
Academic Article
|
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
|
|
Academic Article
|
Targeting Crohn's disease.
|
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis.
|
|
Academic Article
|
Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis.
|
|
Academic Article
|
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
|
|
Academic Article
|
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel.
|
|
Concept
|
Tumor Necrosis Factor alpha-Induced Protein 3
|
|
Academic Article
|
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
|